Thoracic Fluid Content During Stabilization and Therapeutic De-escalation in Septic Shock

Launched by UNIVERSITY HOSPITAL, BREST · Aug 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better monitor fluid levels in patients experiencing septic shock, a severe condition caused by infections that can lead to dangerously low blood pressure and organ failure. The research focuses on a new non-invasive technology called bio-reactance, which can continuously measure the body's fluid content without needing to insert any devices into the body. This could help doctors manage the right amount of fluids given to patients, as too much fluid can lead to serious complications.

To participate in this trial, individuals must be adults over 18 years old and diagnosed with septic shock, which includes having a suspected or confirmed infection and low blood pressure that doesn’t improve with standard fluid treatment. Participants should expect regular monitoring of their fluid levels during their stay in the ICU, which is expected to last more than three days. It’s important to note that those who have been in the ICU for more than three days or have chosen to stop treatment for their condition will not be eligible to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (Age \>18 years old)
• * Septic shock according to Sepsis-3 definition:
• • A suspected or confirmed infection
• • Persisting hypotension, despite adequate fluid resuscitation, requiring vasopressor to maintain a Mean Arterial Pressure (MAP) ≥ 65 mmHg
• • Lactate level \> 2 mmol/l
• • Predictive ICU length of stay \> 3 days
• Exclusion Criteria:
• • Admission in ICU for more than 3 days
• • Refusal to participate
• • Moribund patients
• • Decision of therapeutic withdrawal
• • Curators